Cambrex’s Post

More companies are focusing on developing weight management solutions with GLP-1 drugs. A new player has entered the field with an oral drug that, in preclinical studies, demonstrated a 15% weight reduction over 28 days. Exciting advancements in the realm of weight management solutions using GLP-1 drugs are on the horizon. #WeightManagement #GLP1 #HealthcareInnovation

[Event] Adrien C., Senior Associate at AdBio partners, will be part of the jury at the #Pharmaceutical and #Biotech EIC ePitching event. Here’s why this matters: 🌐 Deep Ecosystem Involvement: At AdBio partners, we’re not just observers; we’re active participants. Adrien’s role as a jury member underscores our commitment to fostering innovation and supporting groundbreaking startups. 👨🎓 Sector Expertise: Our team combines medical, scientific, operational, and business expertise. With a deep understanding of the entrepreneurial process, we help startups navigate the intricate landscape of life sciences. 🔬Early-Stage Pioneers: Our early-stage positioning has made us detail and data-oriented. Adrien’s keen eye ensures that we spot hidden gems and nurture them into transformative success stories. We’re not just #investors; we’re entrepreneur's partners. Adrien will be part of the jury alongside other renowned investors. Their collective insights will shape the future of healthcare and biotechnology. We’re excited to witness the impact of their expertise! Stefano Coco Marielle Mailhes Jia-Yi H. Tristan Maguet Miao He, PhD MBA Osnat Hakimi #AdBioPartners #VentureCapital #Innovation #StartupEcosystem

Here are more insights from the Precision in Drug Discovery & Preclinical Summit!🌟 Exciting insights and valuable networking moments captured during the event. It’s inspiring to see industry leaders come together to drive innovation in drug discovery and development! #PDDPSummit #DrugDiscovery #HealthcareInnovation #NetworkingEvent #PrecisionMedicine #LifeSciences #Biotech #Pharma #PharmaceuticalResearch #SanDiegoEvents #IndustryLeadership

Congratulations to our portfolio company, Insilico Medicine, for winning the 2024 Fierce 50 award from Fierce Life Sciences and Fierce Healthcare. According to Ayla Ellison, Editor-in-Chief of Fierce Life Sciences and Healthcare, the annual Fierce 50 special report highlights individuals and companies that are driving progress in the pharmaceutical, healthcare, and biotechnology industries. These 50 outstanding organizations and individuals demonstrate excellence in their fields, and their commitment to innovation, equity, and improving lives is truly commendable. Powered by Pharma.AI, Insilico Medicine has nominated 20 preclinical candidates in its comprehensive portfolio of over 30 assets, with 9 molecules receiving IND approval. #Fierce50 #PharmaAI #BiotechInnovation #HealthcareAwards #PreclinicalResearch #INDApproval #Pharmaceuticals #Innovation #Biotechnology #LifeSciences #QimingPortfolio #QimingHealthcare Read More: https://lnkd.in/gpYEaupN

What's in it for emerging biotechs when partnering with a CDMO for early stage development? James Berrie and Raymond Donninger discuss how the expertise, efficiency and scalability of a CDMO is crucial for efficiently and cost-effectively delivering new therapeutic candidates for an investigational new drug and first-in-human trials. Read the full interview in Pharma Network here: https://lnkd.in/dKXyWrCy #AHealthierWorld #PharmaceuticalManufacturing #CDMO #Biotech #EarlyStageDevelopment

Join our webinar to learn the benefits of combining CRO and CDMO services through ThermoFisher's Accelerator™ Drug Development

Today’s #biotech and #pharma sponsors are facing rising costs, increased competition, and pressure to innovate faster than ever. To stay ahead, maximizing value at every stage of #drugdevelopment is critical—from early-stage research to #clinicaltrials and #commercialization. Join Thermo Fisher Scientific for an upcoming webinar where we’ll share findings from the Tufts Center for the Study of Drug Development on how integrating end-to-end #CDMO and #CRO services and solutions can significantly boost your program's #expectedNetPresentValue (eNPV). In this webinar, you'll learn: • The benefits of leveraging #eNPV modeling for combined #CDMO and #CRO services • How to streamline processes with #ThermoFisher’s Accelerator™ Drug Development • Real-world case studies showcasing successes from #biotech and #pharma sponsors Led by Dr. Joseph DiMasi from Tufts University, as well as Brenda Bruker and Brittany Hall from Thermo Fisher Scientific, this is a can’t-miss event. RSVP by clicking below: http://spr.ly/6046qxNbm

Don't forget to sign up to our webinar to learn how integrating CDMO and CRO services can significantly boost your program's expected Net Present Value

🚀 Meet Biotech/Biopharma/FDA Experts: Key Takeaways from Biocytogen’s Maryland Forum In the journey of personalized medicine, proving efficacy is only part of the equation. How can production be controlled and scaled for drugs tailored to individual patients? At Biocytogen’s recent Maryland forum, experts from biotech, biopharma, and the FDA emphasized that developing personalized drugs requires a more flexible CMC approach that extends beyond proof of concept. Early consideration of feasibility and scalability for the CMC stage is essential. ✨ The discussion also explored additional insights, such as the benefits of early CMC planning & the FDA fast-track program, FDA’s support in drug development prior to IND submission, and the potential of AI to accelerate drug development. Check here to read more: https://lnkd.in/eyzW2-ge Biocytogen is honored to have facilitated this meaningful exchange. Let’s continue advancing science to bring transformative treatments from the lab to patients. 💡🌐 #PersonalizedMedicine #DrugDevelopment #Biotech #Biopharma #FDA #AI #Innovation #CMC #Biocytogen #HealthcareTransformation

We’re excited to announce the launch of Certara’s Early Development Solution, designed to help biotech companies optimize timelines, derisk programs, and improve outcomes in early-stage drug development.   In a rapidly evolving landscape, companies face mounting pressure to demonstrate product viability and move swiftly to first-in-human trials. Certara’s solution provides a dedicated team of experts and a streamlined approach that integrates drug development services, enabling more efficient and data-driven decision-making.   Read more about our early development services here: https://ow.ly/3Kqg50Tr813   Does your biotech need help getting IND-ready? Contact us to schedule a strategy session with one of our experts.   #DrugDevelopment #Biotech #Pharma #Certara #ClinicalTrials #EarlyStage